The Promising Treatment CTP-543: Once or Twice Daily?
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with
Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are
For the latest research article from Dr. J. Donovan, please click on this link: Canaaf June 2017 Thank you Dr. Donovan for